NEW YORK – Abbott said today that it has received US Food and Drug Administration approval for use of its Alinity s System to conduct screening in US blood and plasma centers.
The system, which runs up to 600 tests per hour, has been designed to screen efficiently and within a small space, Abbott said. It added that its automation and flexibility will help blood and plasma centers improve productivity and maintain accuracy within a testing specialty that can require extensive hands-on time.
"Alinity s is a significant leap forward when it comes to speed, automation, and efficiency for blood and plasma screening," Louis Morrone, vice president of transfusion medicine at Abbott, said in a statement.
The system increases the walk-away time to a minimum of three hours, allowing lab professionals to manage other responsibilities while the instrument processes samples. Additionally, they can continuously load and unload samples and supplies without pausing or stopping the system.
Additional platforms in the Alinity series have already received FDA clearances. The Alinity ci-series of instruments for clinical chemistry and immunoassays, for example, have been on the US market for more than a year after receiving FDA clearance in October 2017.